Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2023 06:01 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference

AUSTIN, TX & DURHAM, NC, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
January 09, 2023 07:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023

AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
November 08, 2022 16:30 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights

– Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer; complete data expected midyear 2023 – – Dosed first patient in...
November 07, 2022 08:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

- Data from two distinct GADLEN product candidates, one targeting CD20 and another targeting B7-H3, enhanced γδT cell killing of tumor cells, demonstrating preclinical proof-of-concept in the...
November 03, 2022 08:30 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Participation in Upcoming November Conferences

AUSTIN, TX and DURHAM, NC, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
November 01, 2022 16:30 ET | Source: Shattuck Labs, Inc.

Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022

AUSTIN, TX and DURHAM, NC, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
October 05, 2022 16:30 ET | Source: Shattuck Labs, Inc.

Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12

AUSTIN, TX & DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
September 01, 2022 16:15 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Participation in Upcoming September Conferences

AUSTIN, TX & DURHAM, NC, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
August 11, 2022 07:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights

– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected to begin in Q3’2022 with initial combination data expected...
May 12, 2022 07:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Reports First Quarter 2022 Financial Results and Recent Business Highlights

– Dose escalation ongoing in Phase 1 clinical trial of SL-172154 in platinum-resistant ovarian cancer; combination trial with liposomal doxorubicin on track to begin in 2H’2022; full dose-escalation...